A 2-Part, Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride in Healthy Adult Participants (Part 2)

Number of participants with Adverse Events (AEs)

时间窗: Up to 28 days post last dose

Part 1

Number of participants with Serioues AEs (SAEs)

时间窗: Up to 28 days post last dose

Part 1

Number of participants with vital sign abnormalities

时间窗: Up to 28 days post last dose

Part 1

Body weight

时间窗: Up to 28 days post last dose

Part 1

Number of participants with 12-lead electrocardiogram abnormalities

时间窗: Up to 28 days post last dose

Part 1

Number of participants with physical examination abnormalities

时间窗: Up to 28 days post last dose

Part 1

Number of participants with clinical laboratory assessment abnormalities

时间窗: Up to 28 days post last dose

Part 1

Columbia-Suicide Severity Rating Scale (C-SSRS)

时间窗: On Day 30

Part 1

Maximum observed plasma concentration (Cmax)

时间窗: Up to Day 29

Part 2

Time of maximum observed plasma concentration (Tmax)

时间窗: Up to Day 29

Part 2

Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

时间窗: Up to Day 29

Part 2

Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24))

时间窗: Up to Day 29

Part 2

Apparent total body clearance (CLT/F)

时间窗: Up to Day 29

Part 2

Apparent volume of distribution (Vz/F)

时间窗: Up to Day 29

Part 2

Terminal elimination half-life (T-HALF)

时间窗: Up to Day 29

Part 2